Baidu
map

European Heart Journal:介入治疗后心绞痛未缓解或复发怎么办?

2019-08-16 xujing 中国循环杂志

在经皮冠状动脉介入治疗(PCI)后,20%~40%患者仍有心绞痛。 近期,欧洲心脏杂志发表文章,阐述了PCI术后心绞痛的潜在机制,并提出一种实用的诊疗流程。


在经皮冠状动脉介入治疗(PCI)后,20%~40%患者仍有心绞痛。

近期,欧洲心脏杂志发表文章,阐述了PCI术后心绞痛的潜在机制,并提出一种实用的诊疗流程。

文章指出,PCI术后心绞痛的病理生理学机制复杂,可能与冠状动脉循环的结构和功能改变有关。

造成心绞痛的可能的冠脉结构性原因:由于冠脉狭窄所致,比如支架内再狭窄、明确的支架内血栓形成、冠状动脉病变进展、仍有残余狭窄、弥漫性冠状动脉粥样硬化、心肌桥和自发性冠状动脉夹层。

如果没有冠脉狭窄,但有心绞痛,可能为功能性的,包括心外膜痉挛、微血管痉挛和冠状动脉微血管病变。

冠脉痉挛的临床特征是静息时发生心绞痛,夜间发作,无运动耐力下降。

微血管性心绞痛的临床特征是胸痛时间长,硝酸酯类效果差。

文章指出,尽管症状评估很重要,但经常不足以确定PCI术后心绞痛复发或不能缓解的原因。

文章建议,针对PCI后心绞痛复发,最好选择冠脉造影,以同时可以明确冠脉结构和功能。具体检查手段见下图。

文章提出了经皮冠状动脉介入治疗后持续性或复发性心绞痛患者的诊断流程图,可以帮助临床医生对此类患者进行评估、干预。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728101, encodeId=c4541e28101f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 15 19:34:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357254, encodeId=afa3135e25411, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563131, encodeId=7829156313181, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371402, encodeId=c4ea3e14028e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Aug 17 13:51:15 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-10-15 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728101, encodeId=c4541e28101f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 15 19:34:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357254, encodeId=afa3135e25411, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563131, encodeId=7829156313181, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371402, encodeId=c4ea3e14028e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Aug 17 13:51:15 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-18 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728101, encodeId=c4541e28101f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 15 19:34:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357254, encodeId=afa3135e25411, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563131, encodeId=7829156313181, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371402, encodeId=c4ea3e14028e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Aug 17 13:51:15 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-18 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728101, encodeId=c4541e28101f9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Oct 15 19:34:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357254, encodeId=afa3135e25411, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563131, encodeId=7829156313181, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Aug 18 12:34:00 CST 2019, time=2019-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371402, encodeId=c4ea3e14028e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Aug 17 13:51:15 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-17 一个字-牛

    学习了谢谢分享

    0

相关资讯

Eur Heart J:介入高出血风险定义:警惕终末期肾病和中重度贫血

近期,高出血风险学术研究联盟(ARC-HBR)发布了《2019共识文件:接受经皮冠状动脉介入治疗患者高出血风险的定义》,该共识基于现有证据,提出了高出血风险患者的定义的20条标准,包括14项主要标准和6项次要标准。对接受经皮冠状动脉介入治疗的高出血风险患者的识别和管理具有重要意义,但在定义这一人群方面缺乏标准化。该ARC-HBR共识文件是定义高出血风险的第一个实用方法,该共识旨在为临床试验确定高危

BMJ:ST段抬高心梗介入治疗后,都应收入重症监护室

很多人都知道,一旦发生急性心肌梗死,需要尽快进导管室开通血管,但很少有人知道,这类患者开通血管后需要住重症监护病房(ICU)还是普通病房。目前,只有欧洲相关指南建议这类患者入住ICU。

胎儿结构性心脏病介入治疗专家指导意见 (2019年制定)

先天性心脏病是我国因出生缺陷致婴幼儿死亡的首要原因,发生率为0.6%~0.8%。随着胎儿超声心动图等筛查技术的迅速发展,胎儿心脏畸形、特别是复杂畸形检出率明显提高,可对疾病自然演变进行有效评估。部分心脏畸形在妊娠中晚期可演变进展致心肌不可逆损害,危及胎儿生命,生后预后不良。适时接受胎儿心脏介入治疗(FCI)可及早中断此类疾病进展,解除梗阻性病变,促进心室继续发育,增加生后双心室循环可能,改善远期预

二尖瓣反流介入治疗的超声心动图评价中国专家共识

二尖瓣反流(mitral regurgitation,MR)是最常见的心脏瓣膜疾病。超声心动图目前是MR诊断和评价最重要的影像学方法。随着以MitraClip为代表的MR介入治疗技术的发展,超声心动图对MR的术前评估、术中监测、术后评价变得尤为重要。虽然国际上已经发布了有关MR超声评价的指导性文献,但其内容甚为复杂,临床使用可行性较低,不符合我国国情,且不是专门针对MR介入治疗技术而编写的。目前,

二尖瓣返流的介入治疗

二尖瓣返流(MR)为最常见的心脏瓣膜疾病,是由于二尖瓣瓣叶、瓣环、乳头肌、腱索等器质性或功能性改变导致的二尖瓣病变,即在心脏收缩时心脏二尖瓣关闭不严,使得血液从左心室反向流入左心房。二尖瓣返流发病率为主动脉瓣狭窄(AS)的10倍,据统计,在我国60岁以上二尖瓣返流患病率达13.4%,需治疗的二尖瓣返流(≥3级)达1000万人。

厦门长庚医院医生称,经桡动脉也可进行颈动脉介入治疗

中国台湾高雄长庚纪念医院吴炯仁等研究提示,经桡动脉利用指引导管在主动脉窦部反折顺向行颈部血管检查、治疗是方便、安全可行的。 该方法是作者在临床工作中遇到那些由于主动脉弓血管畸形经股动脉脑血管造影失败的案例,改为由桡动脉完成颈动脉血管检查及治疗的过程中发现的一种治疗方法,称为指引导管反折技术

Baidu
map
Baidu
map
Baidu
map